ID
45976
Description
Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Acute Kidney Injury https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000894 The goal of this study was to identify genetic variants associated with risk for acute kidney injury (AKI) in patients being treated with vancomycin and genetic variants associated with variability in vancomycin pharmacokinetics. AKI is a common adverse drug event and known complication of vancomycin therapy. Known risk factors fail to accurately predict renal toxicity. Our hypothesis, that genetic variants modify the risk of AKI, was tested by performing genome-wide association and linear regression in 429 patients of European descent using the outcome of peak serum creatinine while on vancomycin. We also tested the hypothesis that genetic variants associate with vancomycin pharmacokinetics, using vancomycin trough levels and calculated renal elimination rate constant as outcomes.
Lien
Mots-clés
Versions (1)
- 02/04/2024 02/04/2024 - Madita Rudolph
Détendeur de droits
Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Téléchargé le
2 avril 2024
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000894 Genome Wide Study of Vancomycin
The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
Similar models
The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
C2348585 (UMLS CUI [1,2])
C0392762 (UMLS CUI [1,2])